Panel Calls for Biomarkers in Routine Clinical Alzheimer's Disease Diagnosis
Posted Oct 14 2010 5:00pm
By Bob DeMarco Alzheimer's Reading Room
Clinicians should try to incorporate biomarker data in their diagnosis of patients with Alzheimer's disease or conditions potentially leading to it, an ad hoc expert panel recommended.
Levels of beta-amyloid or tau proteins in cerebrospinal fluid (CSF), or data from MRI or PET scans using amyloid-specific tracers, should be part of the differential diagnosis of Alzheimer-related disorders, according to two dozen members of the International Working Group for New Research Criteria for the Diagnosis of Alzheimer's Disease.
The panel wrote:
"This reliable identification of Alzheimer's disease biomarkers supports a major change in the conceptualization and diagnosis of AD, because both clinical and in-vivo biological manifestations of the disease can now be integrated into the diagnosis...Laboratory and neuroimaging biomarkers are very highly correlated with the neuropathological lesions of AD."
Bob DeMarco is the Founder of the Alzheimer's Reading Room and an Alzheimer's caregiver. Bob has written more than 1,880 articles with more than 95,100 links on the Internet. Bob resides in Delray Beach, FL.